瑞易宁治疗Ⅱ型糖尿病的临床疗效观察

Randomized clinical trial of GLUCOTROL XL, a release-controlled glipizide, in treatment for type 2 diabetes

目的 观察瑞易宁与美吡达治疗Ⅱ型糖尿病疗效的差异。方法 45例Ⅱ型糖尿病患者随机分为服用瑞易宁的治疗组和服用美吡达的对照组。检测服用前后全天血糖谱胰岛素、C肽及糖化血红蛋白情况。结果 两种药物均有较好的降糖效果 ,比较之下瑞易宁组血胰岛素及C肽水平未见增加 ,且无依从性原因退出研究的病例。结论 瑞易宁降糖作用确切 ,依从性好 ,并可能具有减轻胰岛素抵抗的作用。

Objective To compare the clinical efficacy of GLUCOTROL XL , a release controlled glipizide, and MINIDAB , an immediate releasing glipizide in treating type 2 diabetes mellitus. Methods A total of 45 patients were subjected to this randomized clinical trial, with 24 taking 5 mg GLUCOTROL XL  every day before breakfast, and the left 21 administering MINIDAB  at 5 mg 3 times a day. Glucose tolerance, insulin, C peptide and HbA1c were measured before and after treatment. Results Both of GLUCOTROL XL  and MINIDAB  had good results in controlling blood glucose, but the former did not increase the insulin and C peptide level. No patient dropped out of the trial in the GLUCOTROL XL  group. Conclusion GLUCOTROL XL  exerts good effect on controlling blood glucose and decreasing insulin resistance, and has sound pharmacotherapy adherence.